Abstract

Environmental exposures (e.g. pesticides, air pollution, and environmental tobacco smoke) during prenatal and early postnatal development have been linked to a growing number of childhood diseases including allergic disorders and leukemia. Because the immune response plays a critical role in each of these diseases, it is important to study the effects of toxicants on the developing immune system. Children’s unique susceptibility to environmental toxicants has become an important focus of the field of immunotoxicology and the use of immune biomarkers in molecular epidemiology of children’s environmental health is a rapidly expanding field of research. In this review, we discuss how markers of immune status and immunotoxicity are being applied to pediatric studies, with a specific focus on the various methods used to analyze T-helper-1/2 (Th1/Th2) cytokine profiles. Furthermore, we review recent data on the effects of children's environmental exposures to volatile organic compounds, metals, and pesticides on Th1/Th2 cytokine profiles and the associations of Th1/Th2 profiles with adverse health outcomes such as pediatric respiratory diseases, allergies, cancer and diabetes. Although cytokine profiles are increasingly used in children’s studies, there is still a need to acquire distribution data for different ages and ethnic groups of healthy children. These data will contribute to the validation and standardization of cytokine biomarkers for future studies. Application of immunological markers in epidemiological studies will improve the understanding of mechanisms that underlie associations between environmental exposures and immune-mediated disorders.

© 2007 Elsevier Ireland Ltd. All rights reserved.

Keywords: Biomarkers; Immune system; Environmental exposures; Pesticides; Asthma; Health outcomes

1. Importance of using biomarkers to study children’s environmental health

More than 33% of diseases in children less than 5 years of age are caused by environmental exposures (WHO, 2006). The main risk factors include pesticides, air and water pollution, lead, environmental tobacco smoke, infections, and inadequate diet (EPA, 2006). A growing number of childhood diseases such as allergic disorders (e.g. allergic rhinitis, atopic dermatitis, asthma), cancer (e.g. acute lymphoid and myeloid leukemias), and others (e.g. type 1 diabetes) have been linked to environmental exposures during prenatal and early postnatal development. Because the immune response plays a critical role in each of these diseases, it is important to consider the effects of toxicants on children’s developing immune system. In the recent years, children’s susceptibility to environmental exposures has become an important focus of the field of immunotoxicology (Garry, 2004; Holsapple et al., 2004).

Despite the recognition that early childhood represents a critical period of immune development there is a
dearth of data on the distributions of immune parameters in healthy children. Most of the data available for infants and children have been acquired from pediatric populations afflicted with either acute or chronic health conditions, or they have been extrapolated from adult studies. However, children’s immune systems are less developed and, thus potentially more susceptible to environmental exposures (Kovarik and Siegrist, 1998). Moreover, immunological markers and reference values that have been used in adult occupational health studies (Colosio et al., 1999; Vogt, 1991) are being applied in children’s studies, a situation that also is not always appropriate since immune function evolves over time after exposures to environmental antigens. Finally, collecting blood from a pediatric population poses an important ethical issue and while most of the current immunological assays require less than 1 ml of blood, given the invasive nature of blood collection, careful planning is required to maximize the use of these samples (Holland et al., 2003; Neri et al., 2006).

Luster et al. (2005) recently summarized current efforts to identify and implement tests of immune function (e.g. cytokine profiles) in children with various diseases of the immune system. However, several issues remain with this relatively new application of cytokine measurements in children’s studies: (a) lack of data on the distribution of different cytokine levels in normal, healthy children, (b) lack of standardized methods, (c) the fact that cytokine levels measured in peripheral blood on a single occasion represent only a “snapshot” that may not reflect the response that occurs at the target organ.

In this review, examples from the literature and recent data from two studies conducted at the University of California, Berkeley, the Northern California study of childhood leukemia (Ma et al., 2002; Buffler et al., 2005) and the CHAMACOS birth cohort of Latino mothers and children from agricultural community (Eskenazi et al., 2003) are presented to illustrate how cytokine markers have been used to link environmental exposures to cytokine profiles and how these immunological biomarkers can be applied in the study of adverse health outcomes in children.

2. Biomarkers help link environmental exposures to disease outcome

A biological marker (biomarker) is defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological response to a therapeutic intervention” (NIH Biomarkers Definitions Working Group, 2001). Additionally, biological markers are important tools for molecular epidemiology and human biomonitoring studies (NRC, 2006). They have been used in exposure assessment (Metcalf and Orloff, 2004; Aprea et al., 2002; Anwar, 1997) and health risk prediction (Bonassi and Au, 2002). Biological markers of exposure to bioaerosols (e.g. allergens), air pollution, metals, pesticides etc. can provide specific evidence of exposures (Fig. 1) and their relation to outcomes and, thus, aid in the study of how environmental exposures contribute to the development of adverse human health effects.

As has been defined previously for all biomarkers (NIH Biomarkers Definitions Working Group, 2001), a useful immunological biomarker should have the following attributes: (1) clinical relevance (i.e. related to the disease or pathophysiological process of interest), (2) strong, mechanistic molecular or biochemical basis in the pathophysiology of a disease, (3) sensitivity and
specificity with respect to treatment or exposure, (4) reliability, (5) practicality (level of assay invasiveness), and (6) simplicity in use and application (Metcalf and Orloff, 2004; Lesko and Atkinson, 2001). There continues to be a need for human cell-based methods that can be used to assess the immunotoxicity of xenobiotics in a simple, fast, economical and reliable way (Langezaal et al., 2002).

3. Markers of immune status and immunotoxicity

The endpoints most commonly used to study human immune function include cell counts, cell surface activation markers, immunoglobulin levels, responses to mitogen, and expression and secretion of cytokines (Table 1). The choice of immune test depends on the research question. Enumeration of immune cell subsets or a complete blood count (CBC) is used to obtain a general idea of the status of the immune response (i.e. elevated CBC indicates infection). To test for immunosuppression, lymphocytes are treated with mitogens and their proliferative ability is measured. Detection of specific cytokines reveals the state of immune response at that given time (e.g. elevated TNF-α levels reveal a state of inflammation). The applications of these markers in adult clinical and epidemiological studies have been reviewed previously (Vial et al., 1996; Voccia et al., 1999; Colosio et al., 1999; Vogt, 1991). Therefore, only a brief summary of each endpoint will be provided with updated information on cytokine endpoints.

3.1. Cellular phenotype/cell counts

The immune response generally is divided into two categories: innate and adaptive immunity. Macrophages, dendritic, natural killer (NK) cells and the complement system are the main components of the innate branch, whereas B- and T-lymphocytes, which can mature into memory antigen-specific effector cells, are the main effectors of the adaptive branch. However, it now is known that considerable interaction occurs between the two branches (Steinman and Hemmi, 2006; Chan et al., 2006). Thus, as a broad and general indicator of the immune response, one of the initial methods is to determine whether the proportions of cells fall within the normal range; this can be done using fluorochrome-labeled antibodies that are specific for the cluster of differentiation (CD) surface antigen markers for each cell type. For example, in humans, B-cells are identified by the CD19 surface antigen marker, whereas T-cells are identified using CD3.

3.2. Antibodies

Antibodies, also called immunoglobulins (IgS), are glycoprotein molecules produced by B-lymphocytes. These include IgA, IgG1-4, IgD, IgM, and IgE. These antibodies perform various effector functions such as opsonization of antigens for phagocytosis by macrophages and neutrophils (IgG), activation of the classical complement pathway (IgM), mucosal immunity (IgA), and mast cell degranulation during immediate hypersensitivity reactions (IgE) (Abbas and Lichtman, 2005).

3.3. Proliferation tests

This assay tests the ability of T-lymphocytes to proliferate in response to stimulation with their cognate antigen or a polyclonal stimulation such as phytohemagglutinin A (PHA) mitogen or anti-CD3 antibody. If T-cells fail to proliferate in response to these stimuli, or if the response is markedly reduced, this finding suggests that the immune response of the subject has been suppressed or compromised.

Table 1

<table>
<thead>
<tr>
<th>Parameters used to investigate changes in children’s immune system</th>
<th>Parameters</th>
<th>Primary method of detection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td>IgM, IgD, IgG, IgA, IgE,</td>
<td>Plasma levels detected by ELISA</td>
</tr>
<tr>
<td>Cellular phenotype and activation markers</td>
<td>CD3, CD4, CD8, CD11c, CD19, CD25, CD56, CD14, CD69, CD45RO, CD45RA</td>
<td>Blood sample collected and cells that bind antigen specific fluorochrome-labeled antibodies detected by flow cytometry</td>
</tr>
<tr>
<td>Proliferation tests</td>
<td>Thymidine incorporation, mitogenic stimulation (PHA, concavalin A)</td>
<td>Functional assays that require cultures of cells obtained from subject</td>
</tr>
<tr>
<td>Cytokines</td>
<td>IL-2, IL-4, IL-5, IL-10, IL-13, IFN-γ, TNF-α, GM-CSF</td>
<td>Serum or plasma levels, with or without activation, detected by ELISA; flow cytometric detection of intracellular cytokine production</td>
</tr>
<tr>
<td>Chemokines</td>
<td>RANTES, IP-10, MIP-1α, MIP-1β, MDC, TARC</td>
<td>Serum or plasma levels, with or without activation, detected by ELISA; PCR</td>
</tr>
</tbody>
</table>
### Table 2
Examples of cytokines involved in Th1 and Th2 development and function

<table>
<thead>
<tr>
<th>Name</th>
<th>Secreted by</th>
<th>Target cells</th>
<th>Primary activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1β</td>
<td>Macrophages, epithelial cells</td>
<td>T cells, macrophages</td>
<td>Activates macrophages and T cells; induces fever</td>
</tr>
<tr>
<td>IL-2</td>
<td>Th1</td>
<td>Th, Tc, NK</td>
<td>Induces proliferation and migration; up-regulates MHC II expression; up-regulates MHC II expression; increases phagocytic activity</td>
</tr>
<tr>
<td>IL-4</td>
<td>Th2, NK, mast cells</td>
<td>B, mast cells, macrophages</td>
<td>Anti-inflammatory; inhibits synthesis of TNF-α, IL-1, IL-6, IL-2, IFN-γ, TNF-β (from Th1 cells); down-regulates MHC II; promotes development of regulatory T cells (Tr1)</td>
</tr>
<tr>
<td>IL-5</td>
<td>Th2, mast cells, basophils</td>
<td>B</td>
<td>Stimulates proliferation and activation of eosinophils; induces class switch to IgA</td>
</tr>
<tr>
<td>IL-6</td>
<td>Th2, monocytes, macrophages</td>
<td>B, hepatocytes</td>
<td>Promotes terminal differentiation into plasma cells, induces synthesis of acute-phase proteins</td>
</tr>
<tr>
<td>IL-10</td>
<td>Th2</td>
<td>Macrophages, regulatory T</td>
<td>Anti-inflammatory; inhibits synthesis of TNF-α, IL-1, IL-6, IL-2, IFN-γ, TNF-β (from Th1 cells); down-regulates MHC II; promotes development of regulatory T cells (Tr1)</td>
</tr>
<tr>
<td>IL-12</td>
<td>Macrophages, B-cells, dendritic cells</td>
<td>Tc, Th1, NK</td>
<td>Induces differentiation of naive T cells to Th1 and Tc1 effector cells; stimulates production of Th1 cytokines; inhibits Th2 cytokine production</td>
</tr>
<tr>
<td>IL-13</td>
<td>Th2</td>
<td>Macrophages, T cells</td>
<td>Inhibits activation and release of inflammatory cytokine production; inhibits development of Th1 cells; promotes B cell growth and differentiation</td>
</tr>
<tr>
<td>IL-17</td>
<td>Th</td>
<td>T cells, neutrophils</td>
<td>Recent findings suggest that production of IL-17 by effector T cells (newly recognized subset called Th17 cells) plays a role in inflammation</td>
</tr>
<tr>
<td>IL-18</td>
<td>Activated macrophages</td>
<td>T cells, NK</td>
<td>Induces IFN-γ production by T cells and NK cells; favors Th1 induction and later Th2 responses</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>Th1, Tc, NK</td>
<td>Macrophages, many cells</td>
<td>Activates macrophages; increases expression of MHC I and II; inhibits viral replication; suppresses Th2 development; inhibits Th17 development</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Macrophages, mast cells</td>
<td>Tumor cells, inflammatory cells</td>
<td>Induces expression of autocrine growth factors, nuclear proto-oncogenes, and induces signaling pathways that lead to proliferation, stimulates IL-6</td>
</tr>
<tr>
<td>TGF-β</td>
<td>Monocytes; T cells</td>
<td>T cells</td>
<td>Anti-inflammatory; induces IgA secretion; inhibits cell growth; promote development of Foxp3+ regulatory T cells; promotes development of Th17 effector cells</td>
</tr>
</tbody>
</table>

#### 3.4. Cytokines

Cytokines are small molecular weight proteins secreted by immune cells that regulate the duration and intensity of the immune response (Table 2). For example, type 1 cytokines (IFN-γ, IL-12) mediate the removal of malignant cells and cells infected with viruses, whereas type 2 cytokines (IL-4, IL-5, IL-13) mediate the removal of soluble bacterial antigen. Secretion of types 1 and 2 cytokines promotes development of subsets of memory T-helper-1 (Th1) and T-helper-2 (Th2) cells, respectively (Trinchieri et al., 1996; O’Garra, 1998). Two functionally distinct T-helper lymphocyte subsets are differentiated by their signature cytokines: IFN-γ for Th1 lymphocytes and IL-4 for Th2 lymphocytes (Mosmann and Coffman, 1989). Elevated expression of IL-4, IL-5, and IL-13 from basophils, mast cells, and Th2-cells promotes the synthesis of IgE antibodies in B-cells (Yssel et al., 1998). ELISA is the most common method used to assay cytokines in biological samples, however several cytokine assays are now available; these include Luminex and LINCOPlex, a multi-plexed ELISA, RT-PCR, Taqman® real-time PCR, and immunohistochemistry (Whiteside, 2002; Pala et al., 2000; Jason and Larned, 1997).

The majority of epidemiological studies of pediatric immune response traditionally have used ELISA-based methods to detect cytokine levels in peripheral blood collected from subjects. More recently, analysis of cytokine production has been performed with intracellular staining followed by flow cytometry, a more informative and reliable approach since it ascertains cytokine production at the single cell level, and thus achieves higher specificity. Flow cytometric detection of intracellular cytokines is a functional assay that measures the ability of individual immune cells to express types 1 and 2 cytokines after polyclonal stimulation with mitogens (Pala et al., 2000; Prussin, 1997; Jung et al.,
ing allergic disorders, cancer, and others such as type
ated from a normal response. Specific examples will be
whether the immune response is compromised or devi-
function assays currently available can help to evaluate
profile endpoint to the relatively few number of immune
regulated immune response, the addition of a cytokine
specific antigen. In studies of diseases that involve a dys-
cells that have been generated as a result of exposure to a
of exposure because it identifies memory Th1 or Th2
provide a more mechanistic examination of the effect
complement one another, the intracellular cytokine assay
reveal how these cells function. Although the assays
complement one another, the intracellular cytokine assay
can provide a more mechanistic examination of the effect
of exposure because it identifies memory Th1 or Th2
cells that have been generated as a result of exposure to a
specific antigen. In studies of diseases that involve a dys-
regulated immune response, the addition of a cytokine
profile endpoint to the relatively few number of immune
function assays currently available can help to evaluate
whether the immune response is compromised or devi-
ated from a normal response. Specific examples will be
presented to illustrate how these immune markers have
been used in the study of childhood diseases including
allergic disorders, cancer, and others such as type
1 diabetes (Table 3).

4. Th1/Th2 cytokines in the study of children’s
diseases

In a comprehensive study by Heaton et al. (2005),
multiple immune markers were used to differentiate
between various airway disease phenotypes in children.
The authors reported that atopic children were more
likely to have increased Th2 cytokines such as IL-4, IL-5,
IL-13 whereas children with bronchial hyper-reactivity
(one component of the asthma phenotype that also is
observed in children without asthma) were more likely
to have elevated IFN-γ, a Th1 cytokine (Heaton, 2005).
However, these associations of Th1/Th2 are not consist-
ent for all allergic disorders suggesting that different
mechanisms are responsible for various types of aller-
gies. For example, in atopic dermatitis (AD), one study
reports that AD is associated with increased IL-4 Th2
cells (Kawamoto et al., 2006) whereas Machura et al.
(2006) report that children with AD have significantly
lower IL-4 Th2 cells and TNF-α Th1 cells and therefore
no distinct bias towards Th1 or Th2 profiles.

In a study of potential immune mechanisms in the
pathogenesis of pediatric leukemia, Zhang et al. (2000),
applied the flow cytometric method to detect intracellular
Th1/Th2 cytokine production and reported that children
diagnosed with acute lymphocytic leukemia (ALL) had
decreased numbers of Th1 lymphocytes that produce
IL-2 and IFN-γ and increased numbers of Th2 cells
that produce IL-4 (Table 3). Since the detection and
removal of leukemic cells requires a pro-inflammatory
immune response produced by T-helper, T-cytotoxic,
natural killer, and macrophage cells, the reduced num-
bers of Th1 cells that produce pro-inflammatory IFN-γ
potentially could contribute to the lack of inflammatory
response to leukemic cells.

We used the same method of flow cytometry to
evaluate Th1/Th2 cytokines in ALL cases versus acute
myeloid leukemia (AML) (Fig. 2). Children diagnosed
with AML in this pilot study were more likely to have
decreased Th1 but slightly increased Th2 levels (Fig. 3).
These observed differences in cytokine values were not
statistically significant possibly because of the broad
inter-individual variability and a relatively small sample
size (n = 32). A power calculation performed using this
data indicated that approximately 100 samples would
have to be evaluated to differentiate cytokine levels found
in the AML and ALL groups reliably. Together, these
studies demonstrate that Th1/Th2 biomarkers can be
used to examine mechanisms of disease progression and
differentiate between subtypes of a disorder.

5. Sources of Th1/Th2 variability

Many factors can contribute to the variability of
immune biomarkers including host factors (e.g. sex, age,
etnicity, nutrition) and exposure factors (e.g. chemicals,
bioaerosols, season, etc.). These need to be addressed
before the biomarker is used in large-scale epidemiolog-
ical studies. When lymphocyte subsets were analyzed
in 807 children who range in age from newborns to 18
years old, age was found to be an important factor in dis-
tributions of cell types. For example, percent CD4 was
highest at 0–3 months of age (52%) but slowly declined
over time whereas percent CD8 (18% at 0–3 months of
age) increased over time (Shearer et al., 2003). With sig-
nificant efforts undertaken by the researchers to control
for inter- and intra-laboratory variability in their meth-
ods, the variance within age groups was substantial, even
after the outliers (10th percentile) were discarded. Thus,
Table 3
Applications of Th1/Th2 cytokine in studies of children’s immune-mediated disorders

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Subjects</th>
<th>Cytokines assayed</th>
<th>Method used</th>
<th>Biological sample</th>
<th>Findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td>Birth cohort (n = 172)</td>
<td>IFN-γ, TNF-α, IL-4, IL-5, IL-9, IL-10, IL-13</td>
<td>ELISA</td>
<td>Peripheral blood</td>
<td>Atopy is associated with increased Th2; Bronchial hyper-responsiveness is associated with increased Th1</td>
<td>Heaton et al. (2005)</td>
</tr>
<tr>
<td></td>
<td>Children with asthma (n = 33) vs. healthy control</td>
<td>IFN-γ, TNF-α, IL-2, IL-4, IL-5, IL-10</td>
<td>FC*</td>
<td>Exhaled breath condensate</td>
<td>Cytokine levels detectable, but low and collection and processing method needs improvement</td>
<td>Robroeks et al. (2006)</td>
</tr>
<tr>
<td>Allergic rhinitis</td>
<td>Children with allergic rhinitis (n = 29) undergoing immunotherapy</td>
<td>IL-2, IL-4, IL-13, IFN-γ, IL-10, IL-5</td>
<td>ICS/FC* ELISA</td>
<td>Peripheral blood</td>
<td>Sublingual immunotherapy in children with rhinitis did not alter cytokine profiles</td>
<td>Rolinck-Werninghaus et al. (2005)</td>
</tr>
<tr>
<td>Atopic dermatitis</td>
<td>Children with atopic dermatitis (n = 9) vs. healthy control</td>
<td>IFN-γ, IL-4</td>
<td>ICS/FC</td>
<td>Peripheral blood</td>
<td>Compared to controls, atopic dermatitis had higher IL-4 Th2 cells</td>
<td>Kawamoto et al. (2006)</td>
</tr>
<tr>
<td></td>
<td>Children with atopic dermatitis vs. controls</td>
<td>IFN-γ, IL-4, IL-2, TNF-α</td>
<td>ICS/FC</td>
<td>Peripheral blood</td>
<td>Children with AD had significantly lower IL-4 and TNF-α positive cells; no evidence of imbalance towards Th2 in children with AD</td>
<td>Machura et al. (2006)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>Children diagnosed with B-ALL (n = 50) vs. healthy control</td>
<td>IFN-γ, IL-4</td>
<td>ICS/FC</td>
<td>Peripheral blood</td>
<td>ALL associated with increased Th2</td>
<td>Lacyzynski et al. (2005)</td>
</tr>
<tr>
<td></td>
<td>Children diagnosed with B-ALL (n = 45) vs. healthy control</td>
<td>IFN-γ, IL-4, IL-2</td>
<td>ICS/FC</td>
<td>Peripheral blood</td>
<td>ALL associated with increased Th2 and decreased Th1</td>
<td>Zhang et al. (2000)</td>
</tr>
<tr>
<td>Type 1 diabetes</td>
<td>Children diagnosed with type 1 diabetes (n = 10)</td>
<td>IFN-γ, IL-4</td>
<td>mRNA ELISA</td>
<td>Peripheral blood</td>
<td>Th1 IFN-γ levels low at diagnosis but increased with disease progression</td>
<td>Karlsson Faresjo et al. (2004)</td>
</tr>
<tr>
<td></td>
<td>Newly diagnosed diabetes (n = 22) vs. health controls</td>
<td>IFN-γ, IL-4</td>
<td>mRNA, ELISA</td>
<td>Peripheral blood</td>
<td>Increased IFN-γ and IL-4 in mRNA in subjects with new diabetes but no difference in protein</td>
<td>Halminen et al. (2001)</td>
</tr>
</tbody>
</table>

* ICS: intracellular cytokine staining; FC: flow cytometry.
variability cannot be completely explained by methodological differences because genetic, environmental and socio-economic factors may play significant roles (Marti et al., 2002; NRC, 2006).

Prior to analysis of the intracellular Th1/Th2 cytokines profiles in a birth cohort of Latino children in an agricultural community studied in the Children’s Environmental Health Center at UC Berkeley, CHAMACOS (Eskenazi et al., 2003), we conducted a validation study to evaluate and optimize the precision of our method. We determined the normal healthy reference values for children and adult samples collected over a 1-year period, calculated the assay coefficient of variance and found low intra-assay variability (Duramad et al., 2004a,b). We found that age is an important variable to consider when measuring Th1/Th2 cytokine profiles in children. When we compared these data with the results from sub-cohort of these children at 60 months (Fig. 4) a significant increase of Th1 and a slight decrease of Th2 was observed with age. This finding corrobo-
rates observations of an increase in Th1/Th2 ratio from birth till adulthood with a slight decline in the late years of life (Duramad et al., 2004a,b; Kawamoto et al., 2006; Mc Nerlan et al., 2002). More studies will be needed to establish a normal range of cytokines and other immune markers in children of different age, ethnic groups and life conditions, and epidemiologic analyses of biomarkers in relation to health should always include appropriate adjustments for such covariates. Significant inter-individual variability in healthy subjects may be related to a number of factors including environmental and life-style exposures.

6. Environmental exposures and Th1/Th2

Vine et al. (2000) examined the relationship between exposure to environmental toxicants (e.g. organochlorine pesticides, volatile organic compounds, and metals), found in a Superfund site in Aberdeen, North Carolina, on DNA damage and immune function of inhabitants living near the site. Of the immune markers analyzed in the study population of over 200 subjects [these included cell counts, levels of immunoglobulins (Igs), skin prick test, and mitogen stimulation assays] only mitogen proliferation was significantly lower in subjects who lived near the site. There was no significant difference in cell counts (six analyzed) or Igs (four analyzed). The authors acknowledged that these markers were relatively broad indicators of immune function and proposed more specific immune assays (cytokine analysis). However, they did not carry it out because of the cost constraints. Since then, numerous studies have used immune markers that include cytokine profiles, to evaluate the effect of environmental toxicants such as volatile organic compounds (VOCs), pesticides, polychlorinated biphenyls (PCBs), and metals on children’s immunity (Table 4).

Fig. 4. Changes in Th1 and Th2 with age. Intracellular Th1/Th2 cytokines were detected by flow cytometry (Duramad et al., 2004a) in a subset of peripheral blood samples (n = 39 for 12 months old, n = 239 for 24 months old, and n = 153 for 60 months old) from Latino children enrolled in CHAMACOS study (Eskenazi et al., 2003). A statistically significant increase in Th1 and Th1/Th2 ratio but decrease in Th2 was observed between ages 12 and 60 months. (*p < 0.05 and **p < 0.001).

In a study of the effects of VOCs on newborn immune development (n = 85), VOC exposure was measured by passive sampling of the maternal indoor environment and immune function was measured by detection of intracellular IFN-γ and IL-4 cytokine production (Lehmann et al., 2002). The authors report that exposure to naphthalene was associated with increased IL-4 cytokine production and decreased IFN-γ production was associated with trichloroethylene. In other studies, no association was found between children’s exposures to mercury (Bilrha et al., 2003) and IL-10 and TNF-α levels, however increased levels of GM-CSF was associated with children’s exposure to arsenic (Soto-Pena et al., 2006). In a large longitudinal birth cohort study (n = 540) from Czech Republic (Sram, 2001), lymphocyte immunophenotyping was conducted in two groups of mothers and their newborns that lived either in clean air area (Prachatice) or in the area polluted from power plants and coal home heating (Teplice) (Hertz-Picciotto et al., 2006). A significantly lower percent of T lymphocytes and the %CD4 of the total T-cells were observed in both maternal and cord blood in polluted area with a more pronounced decline during winter months. Additionally, after three years of follow up, children born in Teplice experienced a significantly higher rate of otitis media, respiratory and gastrointestinal infections, and pneumonia that indicates air pollution affected their susceptibility. Karmaus et al. (2005) reported immune function biomarkers (cell counts and antibody production) in children exposed to lead and organochlorine compounds in a cross-sectional study. Their findings indicate that lead is associated with increased IgE production, corroborating a prior report by Lutz et al. (1999). However, cytokines profiles were not evaluated. Since IgE production is a direct result of IL-4 (and IL-13) production, it would be important to examine cytokine levels in children exposed to lead in future studies. In
Table 4
Cytokine and other immunological biomarkers used to evaluate potential immunotoxic effects of environmental exposures

<table>
<thead>
<tr>
<th>Environmental toxicant</th>
<th>Subjects</th>
<th>Method of exposure assessment</th>
<th>Immune parameters measured</th>
<th>Findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volatile organic compounds (VOCs)</td>
<td>Neonates (n = 85)</td>
<td>Passive sampling of maternal indoor environment for VOCs</td>
<td>Intracellular IFN-γ and IL-4 cytokine analysis of T cells isolated from cord blood</td>
<td>Naphthalene associated with increased IL-4 cytokine production; Trichloroethylene associated with decreased IFN-γ</td>
<td>Lehmann et al. (2002)</td>
</tr>
<tr>
<td>Environmental tobacco smoke (ETS)</td>
<td>Atopic children, ages: 6–16</td>
<td>Questionnaire survey of parental tobacco smoke</td>
<td>Nasopharyngeal aspirate analyzed for IL-13 levels</td>
<td>ETS augments expression and secretion of IL-13, potentially increasing Th1 response</td>
<td>Felczak et al. (2006)</td>
</tr>
<tr>
<td>Metals</td>
<td>Children ages: 6–10 years (n = 98)</td>
<td>Arsenic levels detected in urine</td>
<td>Cell counts; mitogen-induced proliferation; cytokine production GM-CSF, IL-2, IL-4, IL-10, IFN-γ</td>
<td>Only GM-CSF levels were positively associated with elevated arsenic levels in children</td>
<td>Soto-Pena et al. (2006)</td>
</tr>
<tr>
<td>Mercury</td>
<td>Newborns (n = 47) vs. reference group</td>
<td>Methyl mercury measured in cord blood</td>
<td>Cord blood immune cell subsets and IL-10, TNF-α production</td>
<td>No difference in cell subsets; no association with cytokine secretion</td>
<td>Birlha et al. (2003)</td>
</tr>
<tr>
<td>Pesticides</td>
<td>Children age: 8 years (n = 27)</td>
<td>Questionnaire; detection of dioxin in mother’s breast milk</td>
<td>Diagnosis of allergy; cell counts</td>
<td>Postnatal exposure was associated with increased CD4 counts; negative association between exposure to dioxin and allergy</td>
<td>ten Tusscher et al. (2003)</td>
</tr>
<tr>
<td>Organophosphates (OPs)</td>
<td>Children age: 1–2 years (n = 239)</td>
<td>Questionnaire; detection of OP metabolites in urine</td>
<td>Diagnosis of asthma, wheezing, intracellular IFN-γ and IL-4 cytokine analysis</td>
<td>Increased IL-4 Th2 cells was associated with asthma and wheeze; IFN-γ Th1 associated with breastfeeding and parental occupation in agriculture</td>
<td>Duramad et al. (2006)</td>
</tr>
<tr>
<td>Organochlorines</td>
<td>Neonates (n = 47) vs. reference group</td>
<td>Organochlorine (12 PCB cogeners) measured in cord blood</td>
<td>Cord blood immune cell subsets and IL-10, TNF-α production</td>
<td>Decreased TNF-α in exposed group was associated with DDE, PCB, and hexachlorobenzene exposures</td>
<td>Birlha et al. (2003)</td>
</tr>
<tr>
<td>Hexachlorobenzene Propanil</td>
<td>Children (n = 52) vs. reference group</td>
<td>Exposed vs. non-exposed determined by distance from fields sprayed with propanil</td>
<td>Cell counts, proliferation, IL-2 cytokine production</td>
<td>No significant difference between exposed and unexposed</td>
<td>McClure et al. (2001)</td>
</tr>
</tbody>
</table>
CHAMACOS, a longitudinal birth cohort in Salinas Valley, California (Eskenazi et al., 2003), the relations between early childhood exposures to an agricultural environment and Th1 and Th2 cytokines were investigated in 24 month old children \( (n = 239) \) (Duramad et al., 2006). Exclusive breastfeeding at 1 month and pet ownership were associated with increased Th1 whereas increased Th2 was associated with maternal agricultural work and the presence of gas stove in the home. Bilrha et al. (2003) found that newborns exposed to organochlorines \textit{in utero} had significantly decreased production of TNF-\(\alpha\), an important proinflammatory cytokine, suggesting that these children may be more susceptible to infections. These data indicate further that early exposures to environmental toxicants can directly impact the development and function of children’s immunity.

7. Conclusions and future directions

In the last several years the field of immunotoxicology has advanced in the following areas: increased recognition of the susceptibility of children’s immune systems to environmental exposures (Garry, 2004; Holsapple et al., 2004), extensive validation of the whole blood Th1/Th2 lymphocyte assay for epidemiological use (Hanekom et al., 2004; Godoy-Ramirez et al., 2004; Hoover et al., 2003; Langezaal et al., 2002; Bergeron et al., 2002) Duramad et al., 2004a,b); proposal of immunotoxicity testing tiers (Holsapple et al., 2005), and the use of cytokine markers/assays to identify chemical allergens (Dearman et al., 2003; Kimber and Dearman, 2003).

Limitations exist for all biomarkers currently in use (NRC, 2006) and this is also the case for cytokines and other immunological biomarkers. Given the mechanistic relevance of cytokines in the altered immune response of children’s disorders, this warrants additional validation studies for existing assays, as well as development of the novel methods for application in the rapidly expanding area of molecular epidemiology of children’s environmental health. More work is needed to acquire the distribution data for different age and ethnic groups, especially for novel assays. Further, the interpretation of the role of immune biomarkers can be strengthened in well characterized cohort studies that effectively explore a whole biomarker continuum (e.g. markers of exposure, effect and susceptibility). In summary, incorporation of immune biomarkers is useful for all children’s studies focused on the effects of environmental exposures and diseases with significant environmental component, and could facilitate understanding of the mechanisms that underlie the associations between environmental exposures and immune-mediated disorders.

Acknowledgements

This research was supported by the following grants: 2P01ES009605, R01ES09137, PS42ES04705 and 5R01ES12503 from NIH and R82670901 from EPA. Contribution to data analysis by Drs. M. Kwan and K. Harley, and helpful discussions with Drs. P. Buffler, B. Eskenazi, S. Selvin and M. Lipsett are sincerely appreciated. This paper’s contents are solely the responsibility of the authors and do not necessarily represent the official views of NIEHS or EPA.

References


